CARDIONOVUM, a medical technology company based in Bonn, Germany, develops and commercializes innovative medical devices such as the new generation of DCB and drug-eluting stents for the treatment of coronary and peripheral artery disease.

The company’s pioneering range of DCBs is based on the SAFEPAX® paclitaxel coating matrix which has the lowest wash-off rates on the market. The company’s strong commitment to clinical research ensures a continually deepening and expanding evidence-base in support of the clinical benefits of our products.

Pioneers in medical devices. The worldwide first CE-approved DCB.

With the first DCB market introduction, CARDIONOVUM contributed significantly to the establishment of a new medical device therapy to treat coronary and peripheral artery disease effectively.

CARDIONOVUM consists of R & D staff, with the longest and most profound experience, in developing clinically advanced DCB and DES cardiovascular devices.

“Live Deserves the Best”


Health Care

Life Sciences

Medical Devices

CARDIONOVUM GmbH

Miquel Craven-Bartle Capella

Manel Martinez

Joop Meijer

Nicolas Euzet

Mark Pruefert

Marcello Gramola

Diego Squara

Paolo Silvestri

Monika Mroczkiewicz

Massimo Morero

Aleksandra Grimm

The Leadership Team at CARDIONOVUM GmbH is responsible for setting the strategic direction of the company, overseeing the research and development of cutting-edge medical devices, and ensuring the successful commercialization of their innovative products. This team of senior executives leads the company in achieving its mission to pioneer new therapies in the treatment of coronary and peripheral artery disease, while also driving global sales and marketing efforts to expand the reach and impact of CARDIONOVUM's advanced technologies.

Leadership Team

Finance and Operations

Leadership Team

About

Team members

Other teams at CARDIONOVUM GmbH

Finance and Operations